The project’s objective is to develop a drug candidate for malignant breast cancer patients. The drug candidate will be developed on the DOS47 proprietary platform owned by the parent company - Helix Biopharma.
The plan of the project includes:
• conducting industrial research on: optimization, verification of effectiveness and the mechanism of action of the new drug candidate named V-DOS47;
• preclinical development of the drug candidate,
• experimental development of the new molcule in Phase I / IIa clinical trials
to develop the treatment of breast cancer, with the potential to be used also in other cancer indications. The research also aims at assessing the immunomodulatory potential of V-DOS47.
The project’s milestones will include the results of preclinical studies and phase I / IIa clinical trials of a drug candidate, ready for commercialization. Commercialization will probably be executed as a licensing agreement with a global pharmaceutical company, in order to jointly complete clinical development and enable market launch of the drug.
Project value: PLN 19,794,415.53
Project co-financing by EU: PLN 12,506,955.77
The project is co-financed from the European Regional Development Fund
as part of the Smart Growth Operational Program
Priority axis 1: Support for R&D activity of enterprises
Measure 1.1: R&D projects of enterprises
Sub-measure 1.1.1: Industrial research and development work implemented by enterprises
Co-financing agreement number: POIR.01.01.01-00-1645/15-00